| Course | NR 565 Advanced Pharmacology Fundamentals |
|---|---|
| Week | 4 |
| Paper type | Case analysis |
| Length | About 1,160 words, 5 pages |
| Format | APA 7 student paper |
| School | Chamberlain University |
| Program | MSN, nurse practitioner core |
| Updated | October 2026 |
Free sample paper for NR 565 Week 4
Case Analysis: Seven Weeks Pregnant on Lisinopril With Mild Persistent Asthma, a Trap Inside a Trap, and Why Nifedipine Extended-Release Is Promoted Over Labetalol
Student Name
College of Nursing, Chamberlain University
NR 565: Advanced Pharmacology Fundamentals
Instructor Name
Month Day, Year
Case Analysis: Seven Weeks Pregnant on Lisinopril With Mild Persistent Asthma, a Trap Inside a Trap, and Why Nifedipine Extended-Release Is Promoted Over Labetalol
Given, Implied and Absent
Given. A composite 31-year-old patient with chronic hypertension diagnosed two years ago arrives at a rural clinic having just confirmed a pregnancy at home. The last menstrual period dates the pregnancy at about seven weeks. Current medication is lisinopril 20 mg daily, with home readings averaging 138/88 mm Hg. The patient also has mild persistent asthma, controlled on daily budesonide at a low dose, with albuterol needed about twice a month. Body mass index is 33. Clinic blood pressure is 142/90.
Implied. The pregnancy was not planned, so lisinopril has been taken through early organogenesis. The patient will need both a change in antihypertensive and early prenatal care, including baseline laboratory studies for later comparison if preeclampsia is suspected.
Absent. There is no information about the patient's kidney function or urine protein yet, and no record of previous pregnancies. The analysis notes these as items to obtain at this visit rather than assumptions.
The Drug I Am Not Using: Lisinopril
The standard choice for this patient before pregnancy was an angiotensin-converting enzyme inhibitor, and it now has to stop. Exposure after the first trimester to any drug blocking the renin-angiotensin system can injure the fetal kidneys, reduce amniotic fluid, impair skull development and end in fetal loss, which is why these agents are contraindicated once pregnancy is known (American College of Obstetricians and Gynecologists, 2019). Data on first-trimester exposure are less consistent, but the drug should be discontinued as soon as pregnancy is recognized. The same applies to angiotensin receptor blockers and direct renin inhibitors. The patient is told that stopping now is the important step, and is referred for early ultrasound and counseling about the exposure.
Should Treatment Continue at All?
For years, mild chronic hypertension in pregnancy was often left untreated until pressures reached 160/105. A large multicenter trial published in 2022 overturned that habit: treating mild chronic hypertension to a target below 140/90 lowered the combined rate of severe preeclampsia, early delivery for medical reasons, abruption and perinatal death, and it did so without making small babies more common (Tita et al., 2022). This patient's readings are in the range the trial treated, so the question is not whether to replace lisinopril, but with what.
The Drug I Am Also Not Using: Labetalol
Outside pregnancy, this patient would sit comfortably on any first-line class (Whelton et al., 2018). The usual first replacement in pregnancy is labetalol, a combined alpha and beta blocker with long experience in pregnancy, and it is one of the preferred agents in guidance (American College of Obstetricians and Gynecologists, 2019). This is the second trap. Labetalol's nonselective beta blockade can provoke bronchospasm, and the patient has persistent asthma. Mild, well-controlled asthma does not make labetalol absolutely forbidden, and some clinicians use it cautiously. But a pregnancy can worsen asthma control in about a third of patients, and an alternative with equal standing exists. Labetalol is therefore set aside.
Methyldopa, the oldest option, is not chosen because it is a weaker antihypertensive, must be taken several times daily and often leaves patients tired or low in mood, which would weigh on a patient who works rotating shifts.
The Promoted Second Choice: Nifedipine Extended-Release
Nifedipine extended-release is a preferred first-line agent in pregnancy alongside labetalol (American College of Obstetricians and Gynecologists, 2019), and in the CHAP trial both were commonly used (Tita et al., 2022). The prescription is nifedipine extended-release 30 mg each morning, swallowed whole; the dose can be raised stepwise to as much as 120 mg daily to bring readings under 140/90. Lisinopril stops today. Because lisinopril's effect fades over a day or two, the first dose of nifedipine is taken tomorrow morning.
What the Substitute Costs
Second choices bring their own problems, and an honest analysis lists them. Nifedipine commonly causes headache, flushing, ankle swelling and reflex tachycardia. Headache in pregnancy is also a warning sign of preeclampsia, so the patient must be taught to tell a drug headache from a new or severe one, and the prescriber must not dismiss a headache as a side effect without checking pressure and symptoms. Ankle swelling from nifedipine can mask or mimic edema. The extended-release tablet cannot be crushed or split, and immediate-release nifedipine is not used for chronic control. Cost is modest, but a tablet that must be swallowed whole may be a problem for a patient with nausea in early pregnancy; if vomiting prevents the dose, the patient should call rather than skip days.
Counseling the Patient About the Change
The patient is likely to be frightened by the lisinopril exposure and may want to stop all medicine. The conversation therefore starts with what is known: the main harms from this class occur later in pregnancy, the drug is being stopped now, and an early ultrasound and specialist review will follow. It then explains why blood pressure treatment continues. Treating mild chronic hypertension lowered the chance of serious complications for both the pregnant patient and the baby in a large trial (Tita et al., 2022), so stopping all treatment would replace one worry with another. The patient is taught to take nifedipine at the same time each morning, to swallow it whole, to expect some flushing or headache in the first week and to measure blood pressure at home twice daily. The asthma inhaler continues, and the patient is reassured that controlling asthma is part of a healthy pregnancy. The patient is asked to say the plan back before leaving.
Watching Both Problems at Once
The follow-up plan covers the pregnancy and the asthma together. At this visit: baseline kidney and liver chemistry, a complete blood count and a spot urine protein measurement, so that any later rise can be judged against this week's values. Home blood pressure twice daily with a validated cuff, with a call for readings at or above 160 systolic or 110 diastolic, or symptoms such as severe headache, visual changes or right upper abdominal pain. A visit in one to two weeks to adjust the dose. Low-dose aspirin, 81 mg daily, is recommended from 12 weeks to reduce the risk of preeclampsia in patients with chronic hypertension (American College of Obstetricians and Gynecologists, 2019). For asthma: continue the inhaled corticosteroid, which is safe and important in pregnancy, check symptom control at each visit and make sure the patient has a rescue inhaler.
Referral
The patient is referred to obstetric care before 10 weeks, ideally with a maternal-fetal medicine consultation given the exposure and chronic hypertension, and the referral letter states the medication change and its date.
References
American College of Obstetricians and Gynecologists. (2019). ACOG practice bulletin no. 203: Chronic hypertension in pregnancy. Obstetrics & Gynecology, 133(1), e26-e50. https://doi.org/10.1097/AOG.0000000000003020
Tita, A. T., Szychowski, J. M., Boggess, K., Dugoff, L., Sibai, B., Lawrence, K., Hughes, B. L., Bell, J., Aagaard, K., Edwards, R. K., Gibson, K., Haas, D. M., Plante, L., Metz, T., Casey, B., Esplin, S., Longo, S., Hoffman, M., Saade, G. R., . . . Andrews, W. W. (2022). Treatment for mild chronic hypertension during pregnancy. New England Journal of Medicine, 386(19), 1781-1792. https://doi.org/10.1056/NEJMoa2201295
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., MacLaughlin, E. J., Muntner, P., Ovbiagele, B., Smith, S. C., Spencer, C. C., Stafford, R. S., Taler, S. J., Thomas, R. J., Williams, K. A., . . . Wright, J. T. (2018). 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension, 71(6), e13-e115. https://doi.org/10.1161/HYP.0000000000000065
Reading the NR 565 Week 4 instructions
The case analysis in this week usually presents a patient whose history makes the usual first-line drug unsafe or unsuitable. Expect the prompt to ask you to identify the problem, choose therapy, justify it and plan monitoring. Read the vignette for what is given, what is implied and what is missing. Name the drug you are not using, and why, before naming the one you are. Check whether a second feature of the case removes the next obvious choice as well. Present the promoted agent with its dose and target, then describe what it costs in side effects, convenience or monitoring. Build follow-up that watches the comorbidity and the treated condition together. Cite guidance and trial evidence for each step.
Inside the NR 565 Week 4 example
The sample opens by separating given facts, such as the pregnancy at about seven weeks and the lisinopril, from implied ones, such as exposure during organogenesis, and from missing data, such as kidney function and urine protein. A section names lisinopril as excluded and explains fetal kidney harm later in pregnancy. Another uses a 2022 trial to show that mild chronic hypertension should still be treated. Labetalol is then set aside because of asthma, and methyldopa because of dosing and fatigue. Nifedipine extended-release is written at 30 mg daily with a target under 140/90. Its headache, flushing, edema and the need to swallow it whole are listed. Follow-up adds baseline laboratory tests, home readings, aspirin from 12 weeks, asthma checks and referral.
NR 565 Week 4 rubric: what full points look like
Case analyses here are commonly marked on whether the trap is noticed and named, whether the excluded drug is stated, whether the substitute is dosed with attention to the reason for exclusion and whether follow-up covers both problems. Prescribing straight past the trap costs the most, so this sample names lisinopril as excluded in its own section. Spotting the second exclusion, labetalol in asthma, shows the depth instructors look for. Confirming that treatment should continue, using trial evidence, avoids the opposite error of stopping everything. Listing what nifedipine costs, including a headache that can mimic preeclampsia, shows honesty about the trade. Monitoring that tracks pregnancy and asthma together completes the analysis. Clear APA 7 citations support each decision.
NR 565 Week 4 help: mistakes that cost points
The biggest error in this week is missing the trap and writing the standard drug as if the comorbidity were background. Another is noticing the problem without ever naming the excluded drug, so the reader cannot tell what was avoided. Some papers choose a substitute without adjusting for the very condition that caused the exclusion. Others reassure instead of listing what the second-line agent costs. Many copy the standard follow-up plan and leave out the comorbidity. Spending words retelling the vignette leaves less room for the analysis. Name each excluded drug, check for a second trap, list the substitute's costs and monitor both conditions. If your vignette has a different trap, send the case, and an analysis can be built around it.
Get a NR 565 Week 4 example written to your instructions
Send the vignette your section posted and any element list attached to it, and a full example analysis comes back within 24 to 48 hours, at no charge the first time. The excluded agent, the promotion and the trade-off are all argued in it rather than assumed.
More NR 565 papers and MSN samples
- NR 565 Week 1: Pharmacokinetics Discussion Post
- NR 565 Week 2: Thiazide Drug Class Write-Up
- NR 565 Week 3: Pneumonia Prescribing Rationale
- NR 565 Week 5: Sample Paper, in Real Form
- NR 565 Week 6: Patient Education Handout
- NR 565 Week 7: Case Analysis
- NR 565 Week 8: Prescribing Rationale
- NR 545 Week 4: Integrated Case Analysis
- NR 509 Week 1: Health History Write-up
- NR 507 Week 4: Case Analysis
NR 565 Week 4 questions, answered
What if the vignette does not say which comorbidity matters?
It rarely says. The design of the week is that the disqualifying detail sits in the history or the laboratory values like any other line, and finding it is part of what gets graded. Read the case for anything altering elimination, bleeding risk, cardiac conduction, pregnancy status or seizure threshold, then test each candidate agent against whatever you find.
Can I choose a drug the course has not covered?
Usually yes, if it is defended to the same standard, though some classrooms restrict the field to agents from the assigned readings. Check what your section published before committing to one. An unfamiliar agent needs its dose, its follow-up and its interaction profile handled with the same care as a familiar one, and it earns nothing for novelty by itself.
How much of the vignette should be restated?
Only the parts that later do work. Restating the case in full is the easiest way to spend a third of the word count on material the instructor wrote, and it crowds out the comparative reasoning carrying the points. Pull forward the findings you will use to exclude or to dose, and leave everything else where the classroom put it.
Where can I find a free NR 565 Week 4 sample paper?
The pregnancy and lisinopril case above, which names two excluded drugs before promoting nifedipine, is the complete NR 565 Week 4 sample. A case analysis on your own vignette can be prepared on request.
Should the NR 565 Week 4 analysis name the drug it is not using?
Yes, explicitly and early. Naming the excluded agent and the reason shows the reader you saw the trap rather than prescribing around it by chance.